Search Results - "Siritanaratkul, Noppadol"

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms by Rungjirajittranon, Tarinee, Owattanapanich, Weerapat, Ungprasert, Patompong, Siritanaratkul, Noppadol, Ruchutrakool, Theera

“…Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most patients…”
Get full text

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma by Robak, Tadeusz, Huang, Huiqiang, Jin, Jie, Zhu, Jun, Liu, Ting, Samoilova, Olga, Pylypenko, Halyna, Verhoef, Gregor, Siritanaratkul, Noppadol, Osmanov, Evgenii, Alexeeva, Julia, Pereira, Juliana, Drach, Johannes, Mayer, Jiri, Hong, Xiaonan, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Cavalli, Franco

“…The substitution of bortezomib for vincristine in R-CHOP resulted in higher rates of complete response and nearly a doubling in progression-free survival among…”
Get full text

Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand by Chuncharunee, Suporn, Teawtrakul, Nattiya, Siritanaratkul, Noppadol, Chueamuangphan, Nonlawan

“…Disease-related complications and management are different among patients with thalassemia. This study was aimed to review the prevalence, clinical risk…”
Get full text

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines by Ekwattanakit, Supachai, Hantaweepant, Chattree, Khuhapinant, Archrob, Siritanaratkul, Noppadol, Viprakasit, Vip

“…Based on Thalassemia International Federation clinical practice guidelines (CPG) for non-transfusion dependent and transfusion dependent thalassemia, several…”
Get full text

Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand by Lekdamrongkul, Pichitra, Pongthavornkamol, Kanaungnit, Molassiotis, Alex, Sriyuktasuth, Aurawamon, Siritanaratkul, Noppadol, Chansatitporn, Natkamol

“…Purposes To investigate health-related quality of life (HR-QoL) and its influencing factors among non-Hodgkin’s lymphoma (NHL) survivors after completion of…”
Get full text

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment by Richardson, Paul G., Hungria, Vânia T.M., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios Athanasios, Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Binlich, Florence, San-Miguel, Jesús F.

“…Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic…”
Get full text

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience by Owattanapanich, Weerapat, Pholmoo, Wikanda, Pongpruttipan, Tawatchai, Siritanaratkul, Noppadol

“…Castleman’s disease (CD) is a rare lymphoproliferative disorder, and its prevalence in Thailand is not known. This 10-year period study investigated the…”
Get full text

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study by Davies, Andrew, Dr, Merli, Francesco, MD, Mihaljevic, Biljana, MD, Siritanaratkul, Noppadol, MD, Solal-Céligny, Phillippe, MD, Barrett, Martin, PhD, Berge, Claude, MSc, Bittner, Beate, PhD, Boehnke, Axel, MD, McIntyre, Christine, PhD, MacDonald, David, MD

“…Summary Background Intravenous rituximab is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent rituximab…”
Get full text

Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients by Hatairaktham, Suneerat, Masaratana, Patarabutr, Hantaweepant, Chattree, Srisawat, Chatchawan, Sirivatanauksorn, Vorapan, Siritanaratkul, Noppadol, Panichkul, Narumol, Kalpravidh, Ruchaneekorn W.

“…Curcuminoids, polyphenol compounds in turmeric, possess several pharmacological properties including antioxidant, iron-chelating, and anti-inflammatory…”
Get full text

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study by Kim, Kihyun, Lee, Jae Hoon, Kim, Jin Seok, Min, Chang Ki, Yoon, Sung Soo, Shimizu, Kazuyuki, Chou, Takaaki, Kosugi, Hiroshi, Suzuki, Kenshi, Chen, Wenming, Hou, Jian, Lu, Jin, Huang, Xiao‐Jun, Huang, Shang‐Yi, Chng, Wee Joo, Tan, Daryl, Teoh, Gerrard, Chim, Chor Sang, Nawarawong, Weerasak, Siritanaratkul, Noppadol, Durie, Brian G.

“…The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic…”
Get full text

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial by Davies, Andrew, Dr, Merli, Francesco, MD, Mihaljević, Biljana, Prof, Mercadal, Santiago, MD, Siritanaratkul, Noppadol, MD, Solal-Céligny, Philippe, MD, Boehnke, Axel, MD, Berge, Claude, MSc, Genevray, Magali, MD, Zharkov, Artem, MD, Dixon, Mark, MSc, Brewster, Michael, BSc, Barrett, Martin, PhD, MacDonald, David, MD

“…Summary Background Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5–6 h. A subcutaneous formulation…”
Get full text

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial by San-Miguel, Jesús F, Prof, Hungria, Vania T M, MD, Yoon, Sung-Soo, Prof, Beksac, Meral, Prof, Dimopoulos, Meletios A, Prof, Elghandour, Ashraf, Prof, Jedrzejczak, Wieslaw W, Prof, Günther, Andreas, MD, Nakorn, Thanyaphong N, MD, Siritanaratkul, Noppadol, MD, Schlossman, Robert L, MD, Hou, Jian, Prof, Moreau, Philippe, Prof, Lonial, Sagar, Prof, Lee, Jae H, Prof, Einsele, Hermann, Prof, Sopala, Monika, PhD, Bengoudifa, Bourras-Rezki, MS, Binlich, Florence, MD, Richardson, Paul G, Prof

“…Summary Background Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus…”
Get full text

Whole exome sequencing and rare variant association study to identify genetic modifiers, KLF1 mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia by Hantaweepant, Chattree, Suktitipat, Bhoom, Pithukpakorn, Manop, Chinthammitr, Yingyong, Limwongse, Chanin, Tansiri, Nawaporn, Sawatnatee, Surasak, Takpradit, Chayamon, Rotchanapanya, Wannaphorn, Pongudom, Saranya, Charoenprasert, Kanyaporn, Paiboonsukwong, Kittiphong, Thamprasert, Wichuda, Nolwachai, Narumol, Rattanasawat, Wanlapa, Sae-Aeng, Busakorn, Khorwanichakij, Nisachon, Saetow, Putchong, Saengboon, Supawee, Kamjornpreecha, Krittichat, Pholmoo, Wikanda, Dujjawan, Boonyanuch, Siritanaratkul, Noppadol

“…Clinical manifestations of patients with Hemoglobin E/beta-thalassemia vary from mild to severe phenotypes despite exhibiting the same genotype. Studies have…”
Get full text

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study by Robak, Tadeusz, Huang, Huiqiang, Jin, Jie, Zhu, Jun, Liu, Ting, Samoilova, Olga, Pylypenko, Halyna, Verhoef, Gregor, Siritanaratkul, Noppadol, Osmanov, Evgenii, Pereira, Juliana, Mayer, Jiri, Hong, Xiaonan, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Cavalli, Franco

“…The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab,…”
Get full text

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study by Verhoef, Gregor, Robak, Tadeusz, Huang, Huiqiang, Pylypenko, Halyna, Siritanaratkul, Noppadol, Pereira, Juliana, Drach, Johannes, Mayer, Jiri, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, Cakana, Andrew, van de Velde, Helgi, Cavalli, Franco

“…In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not…”
Get full text

Quantitative proteomics of plasma vesicles identify novel biomarkers for hemoglobin E/β-thalassemic patients by Kittivorapart, Janejira, Crew, Vanja Karamatic, Wilson, Marieangela C., Heesom, Kate J., Siritanaratkul, Noppadol, Toye, Ashley M.

“…Hemoglobin E (HbE)/β-thalassemia has a wide spectrum of clinical manifestations that cannot be explained purely by its genetic background. Circulating…”
Get full text

Glutathione Redox System in β-Thalassemia/Hb E Patients by Siritanaratkul, Noppadol, Panichkul, Narumol, Charoensakdi, Ratiya, Hatairaktham, Suneerat, Tangjaidee, Thongchai, Kalpravidh, Ruchaneekorn W., Fucharoen, Suthat

“…β-thalassemia/Hb E is known to cause oxidative stress induced by iron overload. The glutathione system is the major endogenous antioxidant that protects animal…”
Get full text

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma by Chutima Kunacheewa, Noppadol Siritanaratkul

“…Objective: Lenalidomide is an immunomodulatory agent with proven efficacy in the treatment of multiple myeloma. In large global clinical studies, lenalidomide…”
Get full text

A prospective analysis for prevalence of complications in Thai nontransfusion‐dependent Hb E/β‐thalassemia and α‐thalassemia (Hb H disease) by Ekwattanakit, Supachai, Siritanaratkul, Noppadol, Viprakasit, Vip

“…Recently, complications in patients with nontransfusion‐dependent thalassemia (NTDT), in particular those with β‐thalassemia intermedia (β‐TI), were found to…”
Get full text

Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient by SUKPANICHNANT, S, NARUMOL SRISUTHAPAN HARGROVE, KACHINTORN, U, MANATSATHIT, S, CHANCHAIRUJIRA, T, SIRITANARATKUL, N, AKARAVIPUTH, T, THAKERNGPOL, K

“…Clofazimine-induced crystal-storing histiocytosis is a rare but well-recognized condition in the literature. Besides the common reddish discoloration of the…”
Get full text